Cel-Sci (NYSEAMERICAN:CVM) Trading 10% Higher – Still a Buy?

Shares of Cel-Sci Corporation (NYSEAMERICAN:CVM – Get Free Report) traded up 10% on Friday . The company traded as high as $1.5599 and last traded at $1.43. 1,114,174 shares traded hands during mid-day trading, an increase of 59% from the average session volume of 700,046 shares. The stock had previously closed at $1.30.

Cel-Sci Price Performance

The stock has a 50 day moving average of $3.29 and a two-hundred day moving average of $4.92. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.35 and a current ratio of 1.39. The firm has a market capitalization of $12.14 million, a P/E ratio of -0.15 and a beta of 0.70.

Get Cel-Sci alerts:

Cel-Sci (NYSEAMERICAN:CVM – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its stake in shares of Cel-Sci by 133.0% in the 1st quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock valued at $115,000 after acquiring an additional 20,484 shares in the last quarter. XTX Topco Ltd acquired a new stake in Cel-Sci in the 4th quarter valued at approximately $66,000. State Street Corp grew its holdings in Cel-Sci by 9.9% in the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after buying an additional 2,300 shares during the last quarter. Jane Street Group LLC acquired a new stake in Cel-Sci in the 4th quarter valued at approximately $83,000. Finally, HRT Financial LP acquired a new stake in Cel-Sci in the 4th quarter valued at approximately $60,000. 12.08% of the stock is owned by institutional investors.

About Cel-Sci

(Get Free Report)

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.

Featured Articles

• Five stocks we like better than Cel-Sci
• Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
• Japan’s Stealth Bull Market: How U.S. Investors Can Get Exposure
• 3 Stocks to Own If Gas Prices Keep Rising
• 3 Crucial Aerospace Component Makers That Analysts Love

Receive News & Ratings for Cel-Sci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cel-Sci and related companies with MarketBeat.com's FREE daily email newsletter.